<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312474086</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312474086</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Philippines</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Navarra</surname><given-names>SV</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312474086">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203312474086"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Tanangunan</surname><given-names>RMDV</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312474086">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mikolaitis-Preuss</surname><given-names>RA</given-names></name>
<xref ref-type="aff" rid="aff2-0961203312474086">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kosinski</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff3-0961203312474086">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Block</surname><given-names>JA</given-names></name>
<xref ref-type="aff" rid="aff2-0961203312474086">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jolly</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff2-0961203312474086">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203312474086"><label>1</label>University of Santo Tomas Hospital, Manila, Philippines</aff>
<aff id="aff2-0961203312474086"><label>2</label>Rush University Medical Center, Chicago, IL USA</aff>
<aff id="aff3-0961203312474086"><label>3</label>QualityMetrics, Lincoln, RI USA</aff>
<author-notes>
<corresp id="corresp1-0961203312474086">Sandra V Navarra, Section of Rheumatology, Clinical Immunology and Osteoporosis, University of Santo Tomas Hospital, España Blvd., Manila, Philippines. Email: <email>sandra_navarra@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>3</issue>
<fpage>262</fpage>
<lpage>267</lpage>
<history>
<date date-type="received"><day>12</day><month>7</month><year>2012</year></date>
<date date-type="accepted"><day>12</day><month>12</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013. Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec>
<title>Objective</title>
<p>LupusPRO is a disease-targeted patient-reported outcome measure that was developed and validated among US patients with systemic lupus erythematosus (SLE). We report the cross-cultural validation results of the LupusPRO English-language version among Filipino SLE patients.</p>
</sec>
<sec>
<title>Method</title>
<p>The 43-item LupusPRO was pretested in 15 SLE individuals, then administered to 106 SLE patients, along with short-form SF36 and the EQ5D visual analogue scale. A mail/drop-back LupusPRO and change in health status item survey were returned within two to three days. Demographics, clinical and serological characteristics, disease activity and damage measured by PGA, SELENA-SLEDAI, LFA Flare, and SLICC-ACR SLE damage index (SDI) were collected. Internal consistency reliability (ICR), test-retest reliability (TRT), convergent validity (corresponding SF36 domains) and criterion validity (against general health and disease activity measures) were tested. Reported <italic>p</italic> values are two tailed.</p>
</sec>
<sec>
<title>Results</title>
<p>A total of 121 Filipino SLE subjects (95% women, median age 31.0 ± 16 years) with at least a high school level of English instruction participated. Median (IQR) PGA, SLEDAI and SDI were 0.0 (1.0), 2.0 (10) and 0 (1), respectively. ICR exceeded 0.7 for all domains except the lupus symptoms domain. TRT was greater than 0.85 for all LupusPRO domains. Convergent and criterion validity were observed against corresponding SF36 domains and disease activity measures. The tool was well received by patients. Confirmatory factor analysis showed good fit.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>English LupusPRO has fair psychometric properties among SLE patients in the Philippines, and is now available for inclusion in clinical trials and longitudinal studies to test responsiveness to change.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Systemic lupus erythematosus</kwd>
<kwd>quality of life</kwd>
<kwd>patient-reported outcomes</kwd>
<kwd>Philippines</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203312474086" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is associated with poor quality of life (QoL),<sup><xref ref-type="bibr" rid="bibr1-0961203312474086">1</xref>,<xref ref-type="bibr" rid="bibr2-0961203312474086">2</xref></sup> and physicians’ assessment of disease activity does not correlate well with QoL.<sup><xref ref-type="bibr" rid="bibr3-0961203312474086">3</xref></sup> The emotional impact of symptoms like depression rather than disease activity has significant influence on QoL.<sup><xref ref-type="bibr" rid="bibr4-0961203312474086">4</xref></sup> Thus disease-coping mechanisms are crucial to achieve optimal QoL.<sup><xref ref-type="bibr" rid="bibr5-0961203312474086">5</xref></sup> Defining and illustrating health-related QoL (HRQoL) has been conducted among those bearing the impact of SLE symptoms, including emotions, everyday activities (home, work, leisure), independence and cognition.<sup><xref ref-type="bibr" rid="bibr6-0961203312474086">6</xref></sup> In Asia, survival of SLE patients may have vastly improved over the years, but because of its diversity in culture and language, it represents an enormous challenge to healthcare providers on how to assess, deliver and improve HRQoL.<sup><xref ref-type="bibr" rid="bibr7-0961203312474086">7</xref></sup> Patient-reported outcomes (PRO) measures are important in describing health outcomes in SLE, and may serve evaluation, descriptive and predictive functions. It is known that there is a discrepancy among physicians and patients in their respective evaluations of disease.<sup><xref ref-type="bibr" rid="bibr8-0961203312474086">8</xref></sup> Physician-reported outcomes and PROs provide unique information and are important for management of SLE. The United States (US) Food and Drug Administration (FDA) recommends cross-cultural adaptation and validation of existent PRO tools to improve their accessibility and application to patients and research universally.<sup><xref ref-type="bibr" rid="bibr9-0961203312474086">9</xref></sup> LupusPRO, a disease-targeted PRO measure, was developed and validated from and among US patients with SLE.<sup><xref ref-type="bibr" rid="bibr10-0961203312474086">10</xref></sup> Male and female SLE patients of varied ethnicity contributed to its development. It is the most comprehensive quality-of-life PRO measure for SLE patients. As it includes health- and nonhealth-related issues deemed pertinent to QoL by SLE patients, it may also have better applicability to varied SLE patient settings, irrespective of the medical care systems in place. LupusPRO has SLE-pertinent domains that are not fully represented in the currently available SLE PRO measures. We herein report the results of the cross-cultural validation study of the English version of the LupusPRO among SLE patients in the Philippines.</p>
</sec>
<sec id="sec2-0961203312474086" sec-type="methods"><title>Methods</title>
<p>LupusPRO has two constructs: health-related QoL (HRQoL) and nonhealth-related QoL (Non-HRQoL). HRQoL domains are: (1) lupus symptoms, (2) lupus medications, (3) physical health (themes: physical function and role physical), (4) emotional health (themes: emotional function and role emotional,) (5) pain-vitality (themes: fatigue, sleep), and (6) procreation (themes: sexual health and reproduction), (7) cognition, and (8) body image. Non-HRQoL domains are: (1) desires/goals, (2) coping, (3) relationship/social support, and (4) satisfaction with care. Individual domain scores, total HRQoL, and total non-HRQoL scores range from 0 to 100, where higher score signifies better health. The tool has excellent psychometric properties.<sup><xref ref-type="bibr" rid="bibr10-0961203312474086">10</xref></sup></p>
<p>The study was approved by the University of Santo Tomas (UST) Institutional Review Board. Adult patients (≥ 18 years) meeting American College of Rheumatology (ACR) classification criteria for SLE<sup><xref ref-type="bibr" rid="bibr11-0961203312474086">11</xref></sup> were eligible for enrollment if they were able to read and understand English with at least a high school level of education with English as the medium of instruction. LupusPRO was applied to consenting SLE patients receiving longitudinal care at UST Hospital, Manila, Philippines. The tool was pretested in 15 individuals and no language modifications were indicated based on the feedback.</p>
<p>Data on the following variables were collected at baseline visit (T1): Demographic information, clinical and serological characteristics, and disease activity and damage assessment. LupusPRO (T1), Medical outcomes study Short Form SF-36<sup><xref ref-type="bibr" rid="bibr1-0961203312474086">1</xref><xref ref-type="bibr" rid="bibr2-0961203312474086">2</xref></sup> and EuroQoL-EQ5D visual analogue scale<sup><xref ref-type="bibr" rid="bibr13-0961203312474086">13</xref>,<xref ref-type="bibr" rid="bibr14-0961203312474086">14</xref></sup> were self-administered. Patients were handed another LupusPRO at T1 visit to be completed within two to three days (after baseline-T2) and returned to the study site. Higher scores on SF36 denote better health. Disease activity was ascertained using the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-Systemic Lupus Erythematosus Disease activity index (SLEDAI)<sup><xref ref-type="bibr" rid="bibr15-0961203312474086">15</xref></sup> and Lupus Foundation of America (LFA)-defined flare (Yes/No).<sup><xref ref-type="bibr" rid="bibr16-0961203312474086">16</xref></sup> Disease damage was assessed using the Systemic Lupus International Collaborative Clinics-ACR SLE damage index (SLICC-ACR SDI).<sup><xref ref-type="bibr" rid="bibr17-0961203312474086">17</xref></sup></p>
<p>Psychometric properties studied included the following: Internal consistency reliability (ICR) for each domain evaluated using Cronbach’s alpha, where an alpha &gt;0.70 is considered acceptable.<sup><xref ref-type="bibr" rid="bibr18-0961203312474086">18</xref></sup> Test-retest reliability (TRT) was tested by evaluating agreement between the patient responses to each domain at two time points. Construct validity was evaluated based on the strength of the correlation of LupusPRO with related domains on SF-36 using Spearman’s correlation coefficient. Correlations were classified as strong (<italic>r</italic> &gt; 0.5), moderate (0.3 ≤ <italic>r</italic> &lt; 0.5), weak (0.1 ≤ <italic>r</italic> &lt; 0.3) or absent (<italic>r</italic> &lt; 0.1).<sup><xref ref-type="bibr" rid="bibr19-0961203312474086">19</xref></sup> Criterion validity of the LupusPRO was judged based on its correlation with either measures of disease activity, damage or patient-reported change in health status. The conceptual framework (hypothesized item-to-scale relationships) of the LupusPRO was evaluated using confirmatory factor analysis (CFA) appropriate for categorical data. CFA was conducted with the LupusPRO item responses using a robust weighted least squares estimator and the software Mplus.<sup><xref ref-type="bibr" rid="bibr20-0961203312474086">20</xref></sup> Mplus employs a multi-step method for ordinal outcome variables that analyzes a matrix of polychoric correlations rather than covariances. The goodness of fit of the hypothesized item-to-scale relationships (multi-factor) was evaluated with the Comparative Fit Index (CFI) and Tucker-Lewis Index (TLI). CFI and TLI are comparative fit indices, which quantify the amount of difference between the examined model and the independence model (i.e. a standard comparison model that asserts none of the components in the model are related) with higher scores indicating larger differences. It is recommended that these two indices be 0.9 or greater as evidence of acceptable model fit.<sup><xref ref-type="bibr" rid="bibr21-0961203312474086">21</xref></sup> All reported <italic>p</italic> values are two tailed.</p>
</sec>
<sec id="sec3-0961203312474086" sec-type="results"><title>Results</title>
<p>One hundred and twenty-one Filipino patients with SLE (95% women) participated (<xref ref-type="table" rid="table1-0961203312474086">Table 1</xref>). All patients had a high school education or above, with various Asian ethnicities. Fifty-eight percent of the patients were single. The median (IQR) age was 31 (16) years, and had a median (IQR) disease duration of five (eight) years. Eighty-five percent were taking corticosteroids at the time of the study (median (IQR) daily dose 5 (12.5) mg prednisone) and 49% were on hydroxychloroquine. Seventy-one percent of the patients had malar rash, 59% lupus nephritis, 79% arthritis, 71% hematologic involvement, 20% serositis and 21% seizures/psychosis on the ACR classification criteria for SLE.
<table-wrap id="table1-0961203312474086" position="float"><label>Table 1</label><caption><p>Demographic and disease characteristics of Filipino SLE patients</p></caption>
<graphic alternate-form-of="table1-0961203312474086" xlink:href="10.1177_0961203312474086-table1.tif"/>
<table frame="hsides">
<tbody align="left">
<tr>
<td>Age median (IQR) years</td>
<td>31 (16)</td>
</tr>
<tr>
<td>Female (%)</td>
<td>95</td>
</tr>
<tr>
<td>Ethnicity (%)</td>
<td>0.8</td>
</tr>
<tr>
<td> Caucasian</td>
<td>96.6</td>
</tr>
<tr>
<td> Asian</td>
<td>1.7</td>
</tr>
<tr>
<td> Hispanic</td>
<td>0.8</td>
</tr>
<tr>
<td> Other</td>
<td/>
</tr>
<tr>
<td>Marital status (%)</td>
<td>57.9</td>
</tr>
<tr>
<td> Never married</td>
<td>38.0</td>
</tr>
<tr>
<td> Currently married</td>
<td>4.1</td>
</tr>
<tr>
<td> Separated</td>
<td/>
</tr>
<tr>
<td>Education in years (%)</td>
<td>2.5</td>
</tr>
<tr>
<td> &lt;High school</td>
<td>22.3</td>
</tr>
<tr>
<td> High school</td>
<td>65.3</td>
</tr>
<tr>
<td> College/university</td>
<td>9.9</td>
</tr>
<tr>
<td> &gt;college</td>
<td/>
</tr>
<tr>
<td>PGA (median, IQR)</td>
<td>0(1)</td>
</tr>
<tr>
<td>SLEDAI (median, IQR)</td>
<td>2 (10)</td>
</tr>
<tr>
<td>LFA flare present (%)</td>
<td>45.4</td>
</tr>
<tr>
<td>SDI (median, IQR) years</td>
<td>0 (1)</td>
</tr>
<tr>
<td>PCS score (median, IQR)</td>
<td>42.5 (9.5)</td>
</tr>
<tr>
<td>MCS score (median, IQR)</td>
<td>54.8 (8.9)</td>
</tr>
<tr>
<td>EQ5D VAS (median, IQR)</td>
<td>80 (15)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312474086"><p>SLE: systemic lupus erythematosus; IQR: interquartile range; PGA: physician global assessment; SLEDAI: systemic lupus erythematosus disease activity index; LFA: Lupus Foundation of America; SDI: SLE damage index; PCS: physical component summary score; MCS: mental component summary score; EQ5D VAS: EuroQoL visual analogue scale.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The median (IQR) PGA and SLEDAI were 0 (1) and 2 (10), respectively. Flare as defined by LFA criteria was present among 45% of participants at the time of the study. Median (IQR) SDI was 0 (1). Median (IQR) PCS and MCS scores were 42.5 (9.5) and 54.8 (8.9), respectively. Median (IQR) EQ5D VAS was 80 (15) (<xref ref-type="table" rid="table1-0961203312474086">Table 1</xref>). Median scores on the LupusPRO domains are shown in <xref ref-type="table" rid="table2-0961203312474086">Table 2</xref>. Domains most affected included lupus medications, emotional health and desires-goals.
<table-wrap id="table2-0961203312474086" position="float"><label>Table 2</label><caption><p>Descriptive scores of the LupusPRO domains in Filipino lupus patients</p></caption>
<graphic alternate-form-of="table2-0961203312474086" xlink:href="10.1177_0961203312474086-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>LupusPRO domain</th>
<th>Median (IQR)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Lupus symptoms</td>
<td>75 (25)</td>
</tr>
<tr>
<td>Cognition</td>
<td>75 (25)</td>
</tr>
<tr>
<td>Lupus medications</td>
<td>62.5 (37.5)</td>
</tr>
<tr>
<td>Physical health</td>
<td>90 (30)</td>
</tr>
<tr>
<td>Pain-vitality</td>
<td>75 (25)</td>
</tr>
<tr>
<td>Body image</td>
<td>75 (30)</td>
</tr>
<tr>
<td>Emotional health</td>
<td>58.3 (25)</td>
</tr>
<tr>
<td>Procreation</td>
<td>87.5 (37.5)</td>
</tr>
<tr>
<td>Desires-goals</td>
<td>62.5 (31.3)</td>
</tr>
<tr>
<td>Social support</td>
<td>87.5 (25)</td>
</tr>
<tr>
<td>Cope</td>
<td>83.3 (25)</td>
</tr>
<tr>
<td>Satisfaction med care</td>
<td>100 (25)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203312474086"><p>IQR: Interquartile range.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Test-retest reliability of the LupusPRO domains exceeded 0.85 (<xref ref-type="table" rid="table3-0961203312474086">Table 3</xref>). ICR of the domains exceeded 0.70 for all domains except the lupus symptoms domain. Convergent validity with corresponding domains of SF36 was observed (<xref ref-type="table" rid="table3-0961203312474086">Table 3</xref>). The lupus symptoms domain showed correlation with SLEDAI items of arthritis, proteinuria, rash, alopecia and low complements. Criterion validity against disease activity measures (PGA, SLEDAI and LFA flare), and change in health or EQ5D VAS were observed. Significant correlations (<italic>r, p</italic>) between patient-reported change in health (since last visit) with cross-sectional domain scores were noted (<xref ref-type="table" rid="table3-0961203312474086">Table 3</xref>).
<table-wrap id="table3-0961203312474086" position="float"><label>Table 3</label><caption><p>Psychometric properties of LupusPRO in Filipino lupus patients</p></caption>
<graphic alternate-form-of="table3-0961203312474086" xlink:href="10.1177_0961203312474086-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>LupusPRO domain</th>
<th>ICR</th>
<th>TRT</th>
<th>Convergent validity(<italic>r, p</italic> value)</th>
<th>Criterion validity(<italic>r, p</italic> value)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Lupus symptoms</td>
<td>0.66</td>
<td>0.95</td>
<td>SLEDAI-arthritis (–0.24, 0.01) SLEDAI-proteinuria (−0.24, 0.02) SLEDAI-rash (−0.38, 0.0001) SLEDAI-alopecia (−0.41, 0.0001) SLEDAI-low complement (−0.32, 0.002)</td>
<td>LFA flare (−0.36, 0.001) PGA (−0.39, 0.0001) SLEDAI (−0.32, 0.001) Patient change in health (−0.46, 0.04) EQ5D VAS (0.43, 0.0001)</td>
</tr>
<tr>
<td>Cognition</td>
<td>0.79</td>
<td>0.95</td>
<td/>
<td>EQ5D VAS (0.29, 0.02) Patient change in health (−0.30, 0.006)</td>
</tr>
<tr>
<td>Lupus medications</td>
<td>0.72</td>
<td>0.86</td>
<td/>
<td>EQ5D VAS (0.35, 0.001) SDI (−0.23, 0.03)</td>
</tr>
<tr>
<td>Physical health</td>
<td>0.88</td>
<td>0.90</td>
<td>Physical function (0.39, 0.001) Role physical (0.27, 0.007)</td>
<td>EQ5D VAS (0.35, 0.001) SLEDAI (−0.22, 0.02) SLEDAI-arthritis (−0.21, 0.02)</td>
</tr>
<tr>
<td>Pain-vitality</td>
<td>0.85</td>
<td>0.91</td>
<td>Bodily pain (0.69, 0.0001) Vitality (0.48, 0.0001)</td>
<td>Patient change in health (−0.38, 0.002) EQ5D VAS (0.43, 0.0001) PGA (−0.21, 0.03) SLEDAI (−0.27, 0.004) SDI (−0.19, 0.04)</td>
</tr>
<tr>
<td>Body image</td>
<td>0.88</td>
<td>0.96</td>
<td/>
<td>EQ5D VAS (0.46, 0.001)</td>
</tr>
<tr>
<td>Emotional health</td>
<td>0.88</td>
<td>0.93</td>
<td>Mental health (0.46, 0.0001), Role emotional (0.33, 0.0009)</td>
<td>Patient change in health (0.48, 0.03), EQ5D VAS (0.30, 0.006)</td>
</tr>
<tr>
<td>Procreation</td>
<td>0.82</td>
<td>0.94</td>
<td/>
<td>PGA (−0.21, 0.02) Patient change in health (−0.45, 0.05)</td>
</tr>
<tr>
<td>Desires-goals</td>
<td>0.86</td>
<td>0.89</td>
<td/>
<td>EQ5D VAS (0.29, 0.006)</td>
</tr>
<tr>
<td>Social support</td>
<td>0.80</td>
<td>0.95</td>
<td/>
<td>EQ5D VAS (0.28, 0.007)</td>
</tr>
<tr>
<td>Cope</td>
<td>0.72</td>
<td>0.91</td>
<td/>
<td>Patient change in health (0.74, 0.04), EQ5D VAS (0.42, 0.002)</td>
</tr>
<tr>
<td>Satisfaction med care</td>
<td>0.91</td>
<td>0.96</td>
<td/>
<td>EQ5D VAS (0.19, 0.05)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203312474086"><p>ICR: Internal consistency reliability; TRT: test-retest reliability; PGA: physician global assessment; SLEDAI: systemic lupus erythematosus disease activity index; EQ5D VAS: EuroQoL visual analogue scale; LFA: Lupus Foundation of America; SFI: Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) flare index; SDI: systemic lupus erythematosus damage index; PF: physical function; RP: role physical; BP: bodily pain; VT: vitality; MH: mental health; RE: role emotional; PCS: physical component summary score; MCS: mental component summary score.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Results of CFA lend empirical support for the conceptual framework of LupusPRO (<xref ref-type="table" rid="table4-0961203312474086">Table 4</xref>). The model fit for the hypothesized item-to-scale relationships was satisfactory (CFI = 0.94, TLI = 0.95). In addition, item-to-factor loadings representing the hypothesized item-to-scale relationships were also satisfactory. In general, items loaded &gt;0.6 with their respective factor.
<table-wrap id="table4-0961203312474086" position="float"><label>Table 4</label><caption><p>Confirmatory factor analysis of LupusPRO</p></caption>
<graphic alternate-form-of="table4-0961203312474086" xlink:href="10.1177_0961203312474086-table4.tif"/>
<table frame="hsides">
<tbody align="left">
<tr>
<td>Factor 1</td>
<td><bold>Symptoms</bold></td>
<td>Factor analysis</td>
</tr>
<tr>
<td/>
<td>Loss of hair</td>
<td>0.359</td>
</tr>
<tr>
<td/>
<td>New flare</td>
<td>0.607</td>
</tr>
<tr>
<td/>
<td>Lupus flare</td>
<td>0.868</td>
</tr>
<tr>
<td>Factor 2</td>
<td><bold>Cognitive</bold></td>
<td/>
</tr>
<tr>
<td/>
<td>Poor memory</td>
<td>0.665</td>
</tr>
<tr>
<td/>
<td>Lack concentration</td>
<td>0.952</td>
</tr>
<tr>
<td>Factor 3</td>
<td><bold>Medication</bold></td>
<td/>
</tr>
<tr>
<td/>
<td>Meds cause side effects</td>
<td>0.738</td>
</tr>
<tr>
<td/>
<td>Concerned over # of meds</td>
<td>0.924</td>
</tr>
<tr>
<td>Factor 4</td>
<td><bold>Procreation</bold></td>
<td/>
</tr>
<tr>
<td/>
<td>Ability to have baby</td>
<td>0.919</td>
</tr>
<tr>
<td/>
<td>Ability to prevent pregnancy</td>
<td>0.831</td>
</tr>
<tr>
<td>Factor 5</td>
<td><bold>Physical</bold></td>
<td/>
</tr>
<tr>
<td/>
<td>Taking care of personal needs</td>
<td>0.861</td>
</tr>
<tr>
<td/>
<td>Getting in and out of bed</td>
<td>0.907</td>
</tr>
<tr>
<td/>
<td>Fulfilling family responsibilities</td>
<td>0.968</td>
</tr>
<tr>
<td/>
<td>Taking care of dependents</td>
<td>0.895</td>
</tr>
<tr>
<td/>
<td>Burden to family</td>
<td>0.826</td>
</tr>
<tr>
<td>Factor 6</td>
<td><bold>Pain/vitality</bold></td>
<td/>
</tr>
<tr>
<td/>
<td>Woke up feeling worn out</td>
<td>0.620</td>
</tr>
<tr>
<td/>
<td>Felt pain</td>
<td>0.693</td>
</tr>
<tr>
<td/>
<td>Unable to do usual activities</td>
<td>0.907</td>
</tr>
<tr>
<td/>
<td>Performing activities take long</td>
<td>0.939</td>
</tr>
<tr>
<td/>
<td>Limited in kinds of activities</td>
<td>0.906</td>
</tr>
<tr>
<td>Factor 7</td>
<td><bold>Emotional</bold></td>
<td/>
</tr>
<tr>
<td/>
<td>Worried about lupus impact</td>
<td>0.893</td>
</tr>
<tr>
<td/>
<td>Worried about losing income</td>
<td>0.689</td>
</tr>
<tr>
<td/>
<td>Anxious</td>
<td>0.929</td>
</tr>
<tr>
<td/>
<td>Depressed</td>
<td>0.840</td>
</tr>
<tr>
<td/>
<td>Concerned lupus could lead to more…</td>
<td>0.798</td>
</tr>
<tr>
<td/>
<td>Concerned lupus could last a long time</td>
<td>0.780</td>
</tr>
<tr>
<td>Factor 8</td>
<td><bold>Body image</bold></td>
<td/>
</tr>
<tr>
<td/>
<td>Dislike my appearance</td>
<td>0.857</td>
</tr>
<tr>
<td/>
<td>Thought less of myself</td>
<td>0.842</td>
</tr>
<tr>
<td/>
<td>Lacked control over appearance</td>
<td>0.905</td>
</tr>
<tr>
<td/>
<td>Self-conscious about appearance</td>
<td>0.714</td>
</tr>
<tr>
<td/>
<td>Embarrassed about how others …</td>
<td>0.853</td>
</tr>
<tr>
<td>Factor 9</td>
<td><bold>Goals</bold></td>
<td/>
</tr>
<tr>
<td/>
<td>Ability to plan</td>
<td>0.800</td>
</tr>
<tr>
<td/>
<td>Overall life satisfaction</td>
<td>0.940</td>
</tr>
<tr>
<td/>
<td>Enjoyment of life</td>
<td>0.963</td>
</tr>
<tr>
<td/>
<td>Fulfill career goals</td>
<td>0.773</td>
</tr>
<tr>
<td>Factor 10</td>
<td><bold>Support</bold></td>
<td/>
</tr>
<tr>
<td/>
<td>Receive support from friends</td>
<td>0.577</td>
</tr>
<tr>
<td/>
<td>Receive support from family</td>
<td>0.785</td>
</tr>
<tr>
<td>Factor 11</td>
<td><bold>Coping</bold></td>
<td/>
</tr>
<tr>
<td/>
<td>Focus on making situation better</td>
<td>0.714</td>
</tr>
<tr>
<td/>
<td>Learned to live with lupus</td>
<td>0.929</td>
</tr>
<tr>
<td/>
<td>Comfort/strength from religion</td>
<td>0.815</td>
</tr>
<tr>
<td>Factor 12</td>
<td><bold>Satisfaction</bold></td>
<td/>
</tr>
<tr>
<td/>
<td>Dr accessible</td>
<td>0.868</td>
</tr>
<tr>
<td/>
<td>Dr understood</td>
<td>0.944</td>
</tr>
<tr>
<td/>
<td>Dr provided information</td>
<td>0.943</td>
</tr>
<tr>
<td/>
<td>Dr discussed/monitored side effects</td>
<td>0.860</td>
</tr>
<tr>
<td/>
<td><bold>Tests of model fit</bold></td>
<td/>
</tr>
<tr>
<td/>
<td>Confirmatory Fit Index (CFI)</td>
<td>0.937</td>
</tr>
<tr>
<td/>
<td>Tucker Lewis Index (TLI)</td>
<td>0.948</td>
</tr>
</tbody>
</table>
</table-wrap>
</p>
</sec>
<sec id="sec4-0961203312474086" sec-type="discussion"><title>Discussion</title>
<p>The LupusPRO English version was found to be valid and reliable among Filipino SLE patients with English-language literacy. Benchmarks for LupusPRO among Philippine patients with SLE have been also presented. Various items may have different importance or implications on patient health within their own cultural context. This patient population was younger than our US LupusPRO patient data reported previously,<sup><xref ref-type="bibr" rid="bibr10-0961203312474086">10</xref></sup> and this may be partly responsible for significant concerns about medication side effects, emotional health and desires-goals domains among Filipino patients.</p>
<p>SLE patients are known to have worse QoL<sup><xref ref-type="bibr" rid="bibr1-0961203312474086">1</xref>,<xref ref-type="bibr" rid="bibr2-0961203312474086">2</xref></sup> than the age- and gender-matched US population, and it is worse than most common chronic diseases.<sup><xref ref-type="bibr" rid="bibr22-0961203312474086">22</xref></sup> Considering the age at onset of SLE is much younger than most other chronic diseases, and given its predilection to affect women, the potential for cumulative impact of SLE on the patients and their family<sup><xref ref-type="bibr" rid="bibr19-0961203312474086">19</xref></sup> is immense. Hence to know the full spectrum of impact of the disease on patients’ daily lives, assessments of their QoL in context of their lupus, HRQoL as well as NHRQoL, are important. LupusPRO is the only disease-specific tool that currently allows that. Furthermore, LupusPRO was derived from SLE patients’ feedback directly, and these patients included men and people of various ethnicities. It has unique domains, and some of these are not included in current disease-specific tools. Examples include lupus symptoms, lupus medications, cognition, procreation, vitality, body image, desires-goals, social support, coping and satisfaction with care. Body image and cognition domains of LupusPRO have been validated against specific cognition and body image measures. The tool represents issues deemed pertinent by male and female SLE patients that affect their quality of life. The items are designed in gender-neutral language. SLE patients experience various stressors because of the need for lupus-related medical care adversely affecting their HRQoL and non-HRQoL. The presence or absence of at least some of these stressors may be due to the nature, affordability and quality of the healthcare system available, coping styles and support available. LupusPRO is able to capture these issues in patients within healthcare system variations observed within groups of patients or countries. Validation of LupusPRO domains against LFA flare and EQ5D VAS measures is also a unique feature of this study.</p>
<p>Compared to the US validation study,<sup><xref ref-type="bibr" rid="bibr10-0961203312474086">10</xref></sup> this Filipino LupusPRO validation had slightly lower ICR values for lupus symptoms, cognition, pain-vitality, body image, and desires-goals (<xref ref-type="table" rid="table5-0961203312474086">Table 5</xref>). This difference may be attributed to the greater variability in the local interpretation of terminologies for these items (e.g. flare, pain, depressed).
<table-wrap id="table5-0961203312474086" position="float"><label>Table 5</label><caption><p>Internal consistency reliability difference between US and Philippine validation</p></caption>
<graphic alternate-form-of="table5-0961203312474086" xlink:href="10.1177_0961203312474086-table5.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Domain</th>
<th colspan="2">ICR</th>
</tr>
<tr><th>US validation</th>
<th>PH validation</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Lupus symptoms</td>
<td>0.72</td>
<td>0.66</td>
</tr>
<tr>
<td>Cognition</td>
<td>0.92</td>
<td>0.79</td>
</tr>
<tr>
<td>Lupus medications</td>
<td>0.68</td>
<td>0.72</td>
</tr>
<tr>
<td>Physical health</td>
<td>0.85</td>
<td>0.88</td>
</tr>
<tr>
<td>Pain-vitality</td>
<td>0.92</td>
<td>0.85</td>
</tr>
<tr>
<td>Emotional health</td>
<td>0.92</td>
<td>0.88</td>
</tr>
<tr>
<td>Procreation</td>
<td>0.72</td>
<td>0.82</td>
</tr>
<tr>
<td>Body image</td>
<td>0.94</td>
<td>0.88</td>
</tr>
<tr>
<td>Desires/goals</td>
<td>0.91</td>
<td>0.86</td>
</tr>
<tr>
<td>Coping</td>
<td>0.76</td>
<td>0.72</td>
</tr>
<tr>
<td>Social support</td>
<td>0.81</td>
<td>0.80</td>
</tr>
<tr>
<td>Satisfaction with care</td>
<td>0.92</td>
<td>0.91</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0961203312474086"><p>ICR: Internal consistency reliability; US: United States of America; PH: Philippines.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Limitations of the study include the fact that most patients were educated and thus generalizability of its results among non- or low educational level patients is not known. Even though 45% had ongoing flare using the LFA definition, the study group had mildly active disease. Responsiveness of the tool was not studied; however, this is planned in the near future with its inclusion in ongoing clinical trials.</p>
<p>The LupusPRO English version has fair psychometric properties among Filipino patients with SLE. Following translation into the Filipino (Tagalog) language and further validation, both language versions will be made available to be included in clinical trials and longitudinal studies for testing of responsiveness to change.</p>
</sec>
</body>
<back>
<sec id="sec5-0961203312474086"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec6-0961203312474086"><title>Conflict of interest statement</title>
<p>The authors have no conflicts of interest to declare.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312474086"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jolly</surname><given-names>M</given-names></name><name><surname>Utset</surname><given-names>TO</given-names></name></person-group>. <article-title>Health related quality of life among outpatient systemic lupus erythematosus University of Chicago cohort</article-title>. <source>Arthritis Rheum</source> <year>2003</year>; <volume>48</volume>: <fpage> 3642</fpage>–<lpage> 3642</lpage>.</citation></ref>
<ref id="bibr2-0961203312474086"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jolly</surname><given-names>M</given-names></name><name><surname>Pickard</surname><given-names>SA</given-names></name><name><surname>Mikolaitis</surname><given-names>RA</given-names></name><name><surname>Rodby</surname><given-names>RA</given-names></name><name><surname>Sequeira</surname><given-names>W</given-names></name><name><surname>Block</surname><given-names>JA</given-names></name></person-group>. <article-title>LupusQoL-US benchmarks for US patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2010</year>; <volume>37</volume>: <fpage>1828</fpage>–<lpage>1833</lpage>.</citation></ref>
<ref id="bibr3-0961203312474086"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jolly</surname><given-names>M</given-names></name><name><surname>Utset</surname><given-names>TO</given-names></name></person-group>. <article-title>Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life?</article-title> <source>Lupus</source> <year>2004</year>; <volume>13</volume>: <fpage> 924</fpage>–<lpage>926</lpage>.</citation></ref>
<ref id="bibr4-0961203312474086"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moldovan</surname><given-names>I</given-names></name><name><surname>Katsaros</surname><given-names>E</given-names></name><name><surname>Carr</surname><given-names>FN</given-names></name><name><surname>Cooray</surname><given-names>D</given-names></name><name><surname>Torralba</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>The Patient Reported Outcomes in Lupus (PATROL) study: Role of depression in health-related quality of life in a Southern California lupus cohort</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>1285</fpage>–<lpage>1292</lpage>.</citation></ref>
<ref id="bibr5-0961203312474086"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hyphantis</surname><given-names>T</given-names></name><name><surname>Palieraki</surname><given-names>K</given-names></name><name><surname>Voulgari</surname><given-names>PV</given-names></name><name><surname>Tsifetaki</surname><given-names>N</given-names></name><name><surname>Drosos</surname><given-names>AA</given-names></name></person-group>. <article-title>Coping with health-stressors and defence styles associated with health-related quality of life in patients with systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>893</fpage>–<lpage>903</lpage>.</citation></ref>
<ref id="bibr6-0961203312474086"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gallop</surname><given-names>K</given-names></name><name><surname>Nixon</surname><given-names>A</given-names></name><name><surname>Swinburn</surname><given-names>P</given-names></name><name><surname>Sterling</surname><given-names>K</given-names></name><name><surname>Naegeli</surname><given-names>A</given-names></name><name><surname>Silk</surname><given-names>M</given-names></name></person-group>. <article-title>Development of a conceptual model of health-related quality of life for systemic lupus erythematosus from the patient's perspective</article-title>. <source>Lupus</source> <year>2012</year>; <volume>21</volume>: <fpage>934</fpage>–<lpage>943</lpage>.</citation></ref>
<ref id="bibr7-0961203312474086"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thumboo</surname><given-names>J</given-names></name><name><surname>Fong</surname><given-names>KY</given-names></name></person-group>. <article-title>Health-related quality of life of patients with systemic lupus erythematosus in Asia: How can this be improved?</article-title> <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage> 1430</fpage>–<lpage>1435</lpage>.</citation></ref>
<ref id="bibr8-0961203312474086"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alarcón</surname><given-names>GS</given-names></name><name><surname>McGwin</surname><given-names>G</given-names><suffix>Jr</suffix></name><name><surname>Brooks</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Systemic lupus erythematosus in three ethnic groups. XI. Sources of discrepancy in perception of disease activity: A comparison of physician and patient visual analog scale scores</article-title>. <source>Arthritis Rheum</source> <year>2002</year>; <volume>47</volume>: <fpage>408</fpage>–<lpage>413</lpage>.</citation></ref>
<ref id="bibr9-0961203312474086"><label>9</label><citation citation-type="other"><comment>Food and Drug Administration. Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims, <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ohrms/dockets/98fr/06d-0044-gdl0001.pdf">http://www.fda.gov/ohrms/dockets/98fr/06d-0044-gdl0001.pdf</ext-link> (2006, accessed 23.03.2012)</comment>.</citation></ref>
<ref id="bibr10-0961203312474086"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jolly</surname><given-names>M</given-names></name><name><surname>Pickard</surname><given-names>AS</given-names></name><name><surname>Block</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Disease-specific patient reported outcome tools for systemic lupus erythematosus</article-title>. <source>Semin Arthritis Rheum</source> <year>2012</year>; <volume>42</volume>: <fpage>56</fpage>–<lpage>65</lpage>.</citation></ref>
<ref id="bibr11-0961203312474086"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr12-0961203312474086"><label>12</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE</given-names></name></person-group>. <article-title>The SF-36 Health Survey</article-title>. In: <person-group person-group-type="editor"><name><surname>Spiker</surname><given-names>B</given-names></name></person-group> (ed.) <source>Quality of life and pharmacoeconomics in clinical trials</source>. <edition>2nd edn</edition>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Lippincott-Raven</publisher-name>, pp. <fpage>337</fpage>–<lpage>345</lpage>, <year>1996</year>.</citation></ref>
<ref id="bibr13-0961203312474086"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>EuroQoL</surname><given-names>Group</given-names></name></person-group>. <article-title>EuroQoL — a new facility for the measurement of health related quality of life</article-title>. <source>Health Policy</source> <year>1990</year>; <volume>16</volume>: <fpage>199</fpage>–<lpage>208</lpage>.</citation></ref>
<ref id="bibr14-0961203312474086"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Wilke</surname><given-names>CT</given-names></name><name><surname>Pickard</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2009</year>; <volume>36</volume>: <fpage>1209</fpage>–<lpage>1216</lpage>.</citation></ref>
<ref id="bibr15-0961203312474086"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petri</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>MY</given-names></name><name><surname>Kalunian</surname><given-names>KC</given-names></name><etal/></person-group>. <article-title>Combined oral contraceptives in women with systemic lupus erythematosus</article-title>. <source>N Engl J Med</source> <year>2005</year>; <volume>353</volume>: <fpage> 2550</fpage>–<lpage>2558</lpage>.</citation></ref>
<ref id="bibr16-0961203312474086"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruperto</surname><given-names>N</given-names></name><name><surname>Hanrahan</surname><given-names>LM</given-names></name><name><surname>Alarcón</surname><given-names>GS</given-names></name><etal/></person-group>. <article-title>International consensus for a definition of disease flare in lupus</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage> 453</fpage>–<lpage>462</lpage>.</citation></ref>
<ref id="bibr17-0961203312474086"><label>17</label><citation citation-type="other"><comment>Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. <italic>Arthritis Rheum</italic> 1996; 39: 363–369</comment>.</citation></ref>
<ref id="bibr18-0961203312474086"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hays</surname><given-names>RD</given-names></name><name><surname>Anderson</surname><given-names>R</given-names></name><name><surname>Revicki</surname><given-names>D</given-names></name></person-group>. <article-title>Psychometric considerations in evaluating health-related quality of life measures</article-title>. <source>Qual Life Res</source> <year>1993</year>; <volume>2</volume>: <fpage>441</fpage>–<lpage>449</lpage>.</citation></ref>
<ref id="bibr19-0961203312474086"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thakkar</surname><given-names>A</given-names></name><name><surname>Mikolaitis</surname><given-names>RA</given-names></name><name><surname>Block</surname><given-names>JA</given-names></name><name><surname>Jolly</surname><given-names>M</given-names></name></person-group>. <article-title>Caregiver burden is associated with worse dyadic relationship and health outcomes in lupus?</article-title> <source>Arthritis Rheum Suppl</source> <year>2011</year>; <volume>63</volume>: <fpage>1422</fpage>–<lpage>1422</lpage>.</citation></ref>
<ref id="bibr20-0961203312474086"><label>20</label><citation citation-type="other"><comment>Mplus User's Guide. Version 1. Los Angeles: Muthén &amp; Muthén, 1998</comment>.</citation></ref>
<ref id="bibr21-0961203312474086"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Bentler</surname><given-names>PM</given-names></name></person-group>. <article-title>Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives</article-title>. <source>Struct Equ Modeling</source> <year>1999</year>; <volume>6</volume>: <fpage>1</fpage>–<lpage>55</lpage>.</citation></ref>
<ref id="bibr22-0961203312474086"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jolly</surname><given-names>M</given-names></name></person-group>. <article-title>How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses?</article-title> <source>J Rheumatology</source> <year>2005</year>; <volume>32</volume>: <fpage>1706</fpage>–<lpage>1708</lpage>.</citation></ref>
</ref-list>
</back>
</article>